MARLBOROUGH, Mass. / Jan 04, 2024 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the first quarter of fiscal 2024 on Thursday, February 1, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.
Interested participants may listen to the call by dialing (888) 394-8218 (in the United States and Canada) or +1 (773) 305-6853 (for international callers) and referencing access code 5909239. Participants may also click here to join. Participants should dial in 5-10 minutes before the call begins.
Hologic will provide a live and webcast replay of the call on the Company’s website at https://investors.hologic.com. The call will be available there for 30 days. The webcast replay will be available approximately two hours after the call ends.
About Hologic
Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.
| Last Trade: | US$71.65 |
| Daily Change: | 0.89 1.26 |
| Daily Volume: | 7,640,910 |
| Market Cap: | US$16.260B |
December 18, 2024 December 09, 2024 December 02, 2024 November 04, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
